BioLife Solutions (NASDAQ:BLFS) Major Shareholder Casdin Partners Master Fund, L Sells 750,000 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) major shareholder Casdin Partners Master Fund, L sold 750,000 shares of the business’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $28.55, for a total transaction of $21,412,500.00. Following the transaction, the insider owned 5,957,165 shares of the company’s stock, valued at $170,077,060.75. This represents a 11.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Casdin Partners Master Fund, L also recently made the following trade(s):

• On Friday, August 15th, Casdin Partners Master Fund, L sold 500,000 shares of BioLife Solutions stock. The shares were sold at an average price of $24.40, for a total transaction of $12,200,000.00.
• On Monday, August 11th, Casdin Partners Master Fund, L sold 500,000 shares of BioLife Solutions stock. The shares were sold at an average price of $22.60, for a total transaction of $11,300,000.00.

BioLife Solutions Price Performance

NASDAQ BLFS opened at $27.32 on Friday. The company has a market capitalization of $1.31 billion, a PE ratio of -227.65 and a beta of 1.95. The company has a fifty day moving average of $25.74 and a 200 day moving average of $23.46. BioLife Solutions, Inc. has a 1 year low of $19.10 and a 1 year high of $29.55.

BioLife Solutions (NASDAQ:BLFS) last posted its earnings results on Thursday, August 7th. The medical equipment provider reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.31). The business had revenue of $25.42 million for the quarter, compared to analyst estimates of $23.71 million. BioLife Solutions had a negative net margin of 5.39% and a positive return on equity of 0.16%. BioLife Solutions has set its FY 2025 guidance at EPS. Research analysts expect that BioLife Solutions, Inc. will post -0.3 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Stephens assumed coverage on shares of BioLife Solutions in a report on Tuesday, July 22nd. They issued an “overweight” rating and a $30.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 price objective (up previously from $30.00) on shares of BioLife Solutions in a report on Friday, August 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioLife Solutions in a report on Wednesday, October 8th. Finally, Zacks Research cut shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 7th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $31.29.

Institutional Trading of BioLife Solutions

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Squarepoint Ops LLC purchased a new stake in shares of BioLife Solutions during the second quarter worth about $1,482,000. Thrivent Financial for Lutherans increased its stake in shares of BioLife Solutions by 2.6% during the second quarter. Thrivent Financial for Lutherans now owns 27,278 shares of the medical equipment provider’s stock worth $588,000 after purchasing an additional 702 shares in the last quarter. Public Sector Pension Investment Board increased its stake in shares of BioLife Solutions by 10.3% during the second quarter. Public Sector Pension Investment Board now owns 126,465 shares of the medical equipment provider’s stock worth $2,724,000 after purchasing an additional 11,769 shares in the last quarter. CANADA LIFE ASSURANCE Co increased its stake in shares of BioLife Solutions by 9.8% during the second quarter. CANADA LIFE ASSURANCE Co now owns 34,692 shares of the medical equipment provider’s stock worth $747,000 after purchasing an additional 3,110 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in shares of BioLife Solutions by 547.9% during the second quarter. Tower Research Capital LLC TRC now owns 7,133 shares of the medical equipment provider’s stock worth $154,000 after purchasing an additional 6,032 shares in the last quarter. Hedge funds and other institutional investors own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.